Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepG2 cells

Journal of Lipid Research

Volumn 38, Issue 5, 1997, Pages 860-869

  Banfi, Cristina ^a   Risé, Patrizia ^a   Mussoni, Luciana ^a   Galli, Claudio ^a   Tremoli, Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cellular lipid composition; Cultured cells; Fibrinolysis; Free fatty acid; PAI 1 secretion; Triglycerides; Urokinase type plasminogen activator

Indexed keywords

ARACHIDONIC ACID; BOVINE SERUM ALBUMIN; FATTY ACID; INTRALIPID; LINOLEIC ACID; LINOLENIC ACID; LIPOSOME; OLEIC ACID; PHOSPHATIDYLCHOLINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ARTICLE; CELL SECRETION; CONTROLLED STUDY; HEPATOMA CELL; HUMAN; HUMAN CELL; LIPID COMPOSITION; PRIORITY JOURNAL;

ANIMALS; CATTLE; CULTURE MEDIA, CONDITIONED; FATTY ACIDS; HUMANS; LINOLEIC ACID; LINOLEIC ACIDS; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIGLYCERIDES; TUMOR CELLS, CULTURED;

EID: 0030906643     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Collen, D. 1980. On the regulation and control of fibrinolysis. Thromb. Haemost. 43: 77-89.
2. Moroi, M., and N. Aoki. 1976. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J. Biol. Chem. 251: 5956-5965.
3. Dawson, S., and A. Henney. 1992. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis. 95: 105-117.
4. Fay, W. P., A. D. Shapiro, J. L. Shih, R. R. Schleef, and D. Ginsburg. 1992. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N. Engl. J. Med. 327: 1729-1733.
5. Erickson, L. A., G. J. Fici, J. E. Lund, T. P. Boyle, H. G. Polites, and K. R. Marotti. 1990. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature. 346: 74-76.
6. Juhan-Vague, I., J. Valadier, M. C. Alessi, M. F. Aillaud, J. Ansaldi, C. Philip-Joet, P. Holvoet, A. Serradimigni, and D. Collen. 1987. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb. Haemost. 57: 67-72.
7. Tabernero, M. D., A. Estelles, V. Vicente, I. Alberca, and J. Aznar. 1989. Incidence of increased plasminogen acttor inhibitor in patients with deep venous thrombosis and/or pulmonary embolism. Thromb. Res. 56: 565-570.
8. Hamsten, A., B. Wiman, U. de Faire, and M. Blomback. 1985. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313: 1557-1563.
9. Hamsten, A., U. de Faire, G. Walldius, G. Dahlen, A. Szamosi, C. Landou, M. Blomback, and B. Wiman. 1987. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 2: 3-9.
10. Cortellaro, M., E. Cofrancesco, C. Boshetti, L. Mussoni, M. B. Donati, M. Cardillo, M. Catalano, L. Gabrielli, B. Lombardi, G. Specchia, L. Tavazzi, E. Tremoli, E. Pozzoli, and M. Turri, for the PLAT Group. 1993. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. Arterioscler. Thromb. 13: 1412-1417.
11. Hamsten, A., and P. Eriksson. 1994. Fibrinolysis and atheroslerosis: an update. Fibrinolysis. 8(Suppl. 1): 253-262.
12. Mussoni, L., L. Mannucci, M. Sirtori, M. Camera, P. Maderna, L. Sironi, and E. Tremoli. 1991. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler. Thromb. 12: 19-27.
13. Mehta, J., P. Mehta, D. Lawson, and T. Saldeen. 1987. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J. Am. Coll. Cardiol. 9: 263-268.
14. Juhan-Vague, I., P. Vague, M. C. Alessi, C. Badier, J. Valadier, M. F. Aillaud, and C. Atlan. 1987. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete & Metab. 13: 331-336.
15. Stiko-Rahm, A., B. Wiman, A. Hamsten, and J. Nilsson. 1990. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arterioslerosis. 10: 1067-1071.
16. Sironi, L., L. Mussoni, L. Prati, D. Baldassarre, M. Camera, C. Banfi, and E. Tremoli. 1996. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler. Thromb. Vasc. Biol. 16: 89-96.
17. Aviram, M., K. J. Williams, R. A. McIntosh, Y. A. Carpentier, A. R. Tall, and R. J. Deckelbaum. 1989. Intralipid infusion abolishes ability of human serum to cholesterol-load cultured macrophages. Arteriosclerosis. 9: 67-75.
18. Granot, E., R. J. Deckelbaum, S. Eisenberg, Y. Oschry, and G. Bengtsson-Olivecrona. 1985. Core modification of human low-density lipoprotein by artificial triacylglycerol emulsion. Biochim. Biophys. Acta. 833: 308-315.
19. Spector, A. A., and J. C. Hoak. 1969. An improved method for the addition of long chain free fatty acid to protein solutions. Anal. Biochem. 32: 297-302.
20. Holvoet, P., G. Perez, H. Bernar, E. Brouwers, B. Vanloo, M. Rosseneu, and D. Collen. 1994. Stimulation with a monoclonal antibody (mAb4E4) of scavenger-receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation. J. Clin. Invest. 93: 89-98.
21. Loskutoff, D. J., and T. E. Edgington. 1977. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc. Natl. Acad. Sci. USA. 74: 3903-3907.
22. Levin, E. G. 1986. Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells. Blood. 67: 1309-1313.
23. Brown, M. S., Y. K. Ho, and J. L. Goldstein. 1980. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J. Biol. Chem. 255: 9344-9352.
24. Bradford, M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dve binding. Anal. Biochem. 72: 248-254.
25. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for isolation of total lipids from animal tissues. J. Biol. Chem. 226: 497-509.
26. Rouser, G., G. Kritchevsky, A. Yamamoto, G. Simon, C. Galli, and A. J. Bauman. 1969. Diethylaminoethyl and triethylaminoethyl-cellulose column chromatography procedures for phospholipids, glycolipids and pigments. Methods Enzymol. 14: 785-807.
27. Moore, S. A., E. Yoder, S. Murphy, G. R. Dutton, and A. A. Spector. 1991. Astrocytes, not neurons, produce docosahexaenoic acid (22:6 omega-3) and arachidonic acid (20:4 omega-6). J. Neurochem. 56: 518-524.
28. Seiffert, D., N. N. Wagner, and D. J. Loskutoff. 1990. Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor. J. Cell. Biol. 111: 1283-1291.
29. Levin, E. G., D. S. Fair, and D. J. Loskutoff. 1983. Human hepatoma cell line plasminogen activator. J. Lab. Clin. Med. 102: 500-508.
30. Wojta, J., T. Nakamura, A. Fabry, P. Hufnagl, R. Beckmann, K. McGrath, and B. R. Binder. 1994. Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cells. Blood. 84: 151-157.
31. Karikó, K., H. Rosenbaum, A. Kuo, R. B. Zurier, and E. S. Barnathan. 1995. Stimulatory effect of unsaturated fatty acids on the level of plasminogen activator inhibitor-1 mRNA in cultured human endothelial cells. FEBS Lett. 361: 118-122.
32. Chautan, M., Y. Latron, F. Anfosso, M. C. Alessi, H. Lafont, I. Juan-Vague, and G. Nalbone. 1993. Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells. J. Lipid Res. 34: 101-110.
33. Graber, R., C. Sumida, and E. A. Nunez. 1994. Fatty acids and cell signal transduction. J. Lipid Mediat. Cell Signal. 9: 91-116.
34. Slivka, S.R., and D. J. Loskutoff. 1991. Regulation of type 1 plasminogen activator inhibitor synthesis by protein kinase C and cAMP in bovine aortic endothelial cells. Biochim. Biophys. Acta. 1094: 317-322.
35. Tremoli, E., C. Banfi, L. Sironi, M. Porta, D. Baldassarre, and L. Mussoni. 1995. Protein kinase G inhibitors and Gemfibrozil prevent the enhancing effect of very low density lipoproteins on the biosynthesis of plasminogen activator inhibitor type 1 by HepG2 cells. Thromb. Haemost. 73:1006 (Abstract).
36. Chomiki, N., M. Henry, M. C. Alessi, F. Anfosso, and I. Juhan-Vague. 1994. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb. Haemost. 72: 44-53.
37. Busso, N., E. Nicodeme, C. Chesne, A. Guillouzo, D. Belin, and F. Hjafil. 1994. Urokinase and type 1 plasminogen activator inhibitor production by normal human hepatocytes: modulation by inflammatory agents. Hepatology. 20: 186-190.